iTonic Holdings Ltd (Class A) (ITOC) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, iTonic Holdings Ltd (Class A) (NASDAQ: ITOC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.85 (-4.99% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ITOC ranks #827 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ITOC carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 62.6%, and ROIC of -35.0%. By comparison, QTI (QT Imaging Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $32.3M) and IRIX (IRIDEX Corporation) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, ITOC leads on earnings multiple (N/A) while ITOC leads on capital efficiency (-35.0% ROIC).
Per ITOC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001970544), iTonic Holdings Ltd (Class A) generated $523.0K in revenue (+16.7% YoY), -$5.1M in net income, and -$3.2M in free cash flow against $9.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 10.69 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 32.7% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ITOC currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($2.99) forces dealer call-delta covering toward $19.32.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
iTonic Holdings Ltd (Class A) (ITOC) dropped -4.99% to $2.85, trading at 4% of its 52-week range ($2.12 – $18.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BEIJING, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a healthcare company focused on digital medical technologies, today announced that it has received a written notice da
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ITOC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ITOC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, iTonic Holdings Ltd (Class A) (ITOC) ranks #827 by composite RQD confidence (35/100, grade D-) and #830 by equity capitalization ($20.9M). Within this direct 5-issuer industry benchmark cohort, ITOC leads on earnings valuation at N/A trailing P/E, while ITOC leads on capital efficiency and profitability with -35.0% ROIC and 62.6% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with ITOC at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ITOC
ACTIVE
iTonic Holdings Ltd (Class A) | D- | 35/100 | — | 62.6% | -35.0% | -4.99% | $20.9M | Benchmark Subject |
| QTI QT Imaging Holdings Inc. | D- | 38/100 | — | 45.4% | -35.0% | -3.07% | $32.3M | /qti-vs-itoc → |
| IRIX IRIDEX Corporation | E | 34/100 | — | 36.5% | -35.0% | -2.92% | $12.7M | /irix-vs-itoc → |
| POCI Precision Optics Corporation Inc. | E | 34/100 | — | 17.8% | -35.0% | +5.76% | $50.5M | /poci-vs-itoc → |
| NDRA ENDRA Life Sciences Inc. | D | 48/100 | — | — | -35.0% | +2.95% | $7.3M | /ndra-vs-itoc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), iTonic Holdings Ltd (Class A) (ITOC) reported GAAP revenue of $523.0K (+16.7% vs. FY2024 revenue of $448.2K , and -16.8% cumulative change since FY2023) , GAAP net income of -$5.1M, operating cash flow of -$3.2M, and free cash flow of -$3.2M (-317.0% YoY). On the balance sheet, ITOC closed FY2025 with $9.1M in total assets against $0 in total debt (Altman Z-Score: 10.69, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $523.0K | -$5.1M | -$3.2M | -$3.2M | $9.1M | — |
| FY2024 (FY) | 2024-12-31 | $448.2K | -$660.6K | -$775.0K | -$775.9K | $6.7M | — |
| FY2023 (FY) | 2023-12-31 | $628.6K | -$241.2K | -$63.6K | -$63.6K | — | — |
As of 2026-11-01, iTonic Holdings Ltd (Class A) (NASDAQ: ITOC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.85 (-4.99% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ITOC ranks #827 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ITOC carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 62.6%, and ROIC of -35.0%. By comparison, QTI (QT Imaging Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $32.3M) and IRIX (IRIDEX Corporation) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, ITOC leads on earnings multiple (N/A) while ITOC leads on capital efficiency (-35.0% ROIC).
Per ITOC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001970544), iTonic Holdings Ltd (Class A) generated $523.0K in revenue (+16.7% YoY), -$5.1M in net income, and -$3.2M in free cash flow against $9.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ITOC last traded at $2.85 (-4.99% on volume of 4,938 shares), positioning the stock -32.94% below its 50-day simple moving average ($4.25) and -45.19% below its 200-day simple moving average ($5.20). Across its 52-week range of $2.12 to $18.40, ITOC sits at the 4.5% percentile with a 14-day RSI of 32.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.49 to $3.21).
Why ITOC Stock dropped -4.99% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.